You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Details for Patent: 8,399,514

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,399,514 protect, and when does it expire?

Patent 8,399,514 protects TECFIDERA and is included in one NDA.

This patent has forty-one patent family members in eighteen countries.

Summary for Patent: 8,399,514

Title:	Treatment for multiple sclerosis
Abstract:	Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.
Inventor(s):	Lukashev; Matvey E. (Tewksbury, MA), O'Neill; Gilmore (Medford, MA)
Assignee:	Biogen Idec MA Inc. (Cambridge, MA)
Application Number:	13/372,426
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,399,514
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 8,399,514

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-001	Mar 27, 2013	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				METHOD OF TREATING MULTIPLE SCLEROSIS	⤷ Sign Up
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-002	Mar 27, 2013	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				METHOD OF TREATING MULTIPLE SCLEROSIS	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,399,514

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2137537	⤷ Sign Up	C300674	Netherlands	⤷ Sign Up
European Patent Office	2137537	⤷ Sign Up	CA 2014 00035	Denmark	⤷ Sign Up
European Patent Office	2137537	⤷ Sign Up	PA2014024	Lithuania	⤷ Sign Up
European Patent Office	2137537	⤷ Sign Up	1490038-5	Sweden	⤷ Sign Up
European Patent Office	2137537	⤷ Sign Up	92487	Luxembourg	⤷ Sign Up
European Patent Office	2137537	⤷ Sign Up	122014000069	Germany	⤷ Sign Up
European Patent Office	2137537	⤷ Sign Up	SPC/GB14/046	United Kingdom	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.